Cholecalciferol attenuates induced Parkinson’s like-disease variation and cellular morphology of striatum and substantial Nigra

Abstract

Parkinson’s disease is the commonest motor neurodegenerative disorder which affects the dopaminergic neurons and causes significant loss of dopamine. 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a selective neurotoxin in the nigrostriatal pathway leading to this motor disorder. Cholecalciferol (Vitamin D3) has been described as an active neurosteriod with antioxidant properties ubiquitously present in the brain. The study hypothesized that stimulation of vitamin D receptor by cholecalciferol could reduce autophagic cell death and degeneration following a state of drug induced parkinsonism in mice. The aim of the research was to observe the cytoarchitectural, histochemical, neurobehavioural and immunohistochemical effects of cholecalciferol on striatum and substantia nigra in mice model of MPTP-induced Parkinson’s disease. Fifty adult male C57BL/6J mice weighing about 25-35g were randomly selected and assigned into 5 groups for this study. The mice were then subjected to neurobehavioural, neurochemical and neuropathological evaluations. The results obtained showed a significant reduction (*p<0.05) in the estimated markers of oxidative stress with high dose of vitamin D3 following MPTP induction. There was also statistical significant reduction (**p<0.01, ***p<0.001) in the expression of GFAP-immuno-positive cells in the substantia nigra of the experimental mice when compared with the control group. It can be inferred that the administration of Vitamin D3 was associated with significant attenuation of focal effects linked with MPTP in mice model of Parkinson’s Disease.Keywords: Aging, Neurodegeneration, Dopaminergic neuron, Vitamin D3, Environmental toxins

Flavonoid glycoside fraction of <i>Ginkgo biloba</i> extract modulates antioxidants imbalance in vanadium-induced brain damage

“…Parkinson's disease is a complicated neurodegenerative disorder where the risk, onset, and development of the illness are influenced by both uncommon and common genetic variations [1] , [2] . Parkinson's disease (PD) is known to be a progressive neurological movement condition that affects 1% of people above the age of 55 and rises 5% by the age of 85 [3] , [4] . It is also a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra, a region of the brain responsible for motor control.…”